Table 2

ORs of inhospital mortality and HRs of overall mortality and adverse cardiac outcomes associated with RA and SLE

Adverse outcomesControl group (n=170 762)Patients with autoimmune diseases
Patients with RA (n=525)Patients with SLE (n=211)
Inhospital mortality (%)3438 (2.0)22 (4.2)11 (5.2)
 Crude OR (95% CI)1.002.13 (1.39 to 3.27)***2.68 (1.46 to 4.91)***
 Adjusted OR (95% CI)†1.001.73 (1.11 to 2.68)*3.81 (2.02 to 7.16)***
Overall mortality (%)45 489 (26.6)199 (37.9)71 (33.6)
 Crude HR (95% CI)1.001.74 (1.51 to 2.00)***1.53 (1.21 to 1.93)***
 Adjusted HR (95% CI)‡1.001.55 (1.35 to 1.79)***2.20 (1.74 to 2.78)***
Ischaemic events (%)49 586 (29.0)157 (29.9)62 (29.4)
 Crude HR (95% CI)1.001.21 (1.03 to 1.41)*1.18 (0.92 to 1.51)
 Adjusted HR (95% CI)‡1.001.18 (1.01 to 1.39)*1.17 (0.91 to 1.50)
Repeat revascularisation (%)61 872 (36.2)171 (32.6)81 (38.4)
 Crude HR (95% CI)1.001.00 (0.86 to 1.16)1.23 (0.99 to 1.52)
 Adjusted HR (95% CI)‡1.001.06 (0.92 to 1.24)1.27 (1.02 to 1.58)*
Any MACE95 824 (56.1)321 (61.1)135 (64.0)
 Crude HR (95% CI)1.001.24 (1.11 to 1.38)***1.34 (1.13 to 1.58)***
 Adjusted HR (95% CI)‡1.001.20 (1.07 to 1.34)**1.47 (1.24 to 1.75)***
  • *p<0.05, **p<0.01, *** p<0.001.

  • †Based on the multiple logistic regression analysis with adjustment for age, sex, medical comorbidities, ACS, stenting and hospital levels.

  • ‡Based on Cox proportional hazards regression model with adjustment for age, sex, medical comorbidities, ACS, stenting and hospital levels.

  • ACS, acute coronary syndrome; MACE, major adverse cardiac events; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.